Exploration of Targeted Anti-tumor Therapy

Disease	Setting	ICIs
OC	NACT first-line		ENGOT OV 43 [60] FIRST [61] ATHENA [62] MITO 28 [63]	AGO DUO [59]
ROC Plat Se	NRG-GY003 [53]	NCT02873962 [77]	ANITA [79] ATALANTE [80]
ROC Plat R		NCT02440425 [52] NCT02873962 [74]	EORTC 1508 [81] NCT02484404 [82]
EC	Advanced (III-IV) recurrent CT naive		LEAP-001 [41] NRG-GY018 [45]	MITO END-3 [44] ATTEND [42] RUBY [43]
Recurrent prior CT	NCT03015129 [37] NCT02982486 [40] NCT02834013 [73]	NCT02899793 [38] KEYNOTE-775 [46] NCT02549209 [45]	MITO END-3 [44] ATTEND [42] NCT02912572 [39] NCT03526432 [83]
CC	LACC	NCT01711515 [74]	MITO CERV 3 [15] NCT04221945 [14]
Recurrent metastatic		NRG-GY002 [75] KEYNOTE-826 [16] REGENERON [19] CX 8 [76]	NCT02921269 [78] BEAT [17]

Disease

Setting

ICIs

CTLA-4

PD-1

PD-L1

Ipilimumab
Tremelimumab

Pembrolizumab
Nivolumab
Dostarlimab
Cemiplimab

Ave
Atezolizumab
Durvalumab

NACT first-line

ENGOT OV 43 [60]
FIRST [61]
ATHENA [62]
MITO 28 [63]

AGO DUO [59]

ROC Plat Se

NRG-GY003 [53]

NCT02873962 [77]

ANITA [79]
ATALANTE [80]

ROC Plat R

NCT02440425 [52]
NCT02873962 [74]

EORTC 1508 [81]
NCT02484404 [82]

Advanced (III-IV) recurrent CT naive

LEAP-001 [41]
NRG-GY018 [45]

MITO END-3 [44]
ATTEND [42]
RUBY [43]

Recurrent prior CT

NCT03015129 [37]
NCT02982486 [40]
NCT02834013 [73]

NCT02899793 [38]
KEYNOTE-775 [46]
NCT02549209 [45]

MITO END-3 [44]
ATTEND [42]
NCT02912572 [39]
NCT03526432 [83]

LACC

NCT01711515 [74]

MITO CERV 3 [15]
NCT04221945 [14]

Recurrent metastatic

NRG-GY002 [75]
KEYNOTE-826 [16]
REGENERON [19]
CX 8 [76]

NCT02921269 [78]
BEAT [17]